Skip to main content
Clinical Trials/TCTR20230417004
TCTR20230417004Enrolling By InvitationPhase 4

A split-face study comparing the incidence of postinflammatory hyperpigmentation following a 532-nm Picosecond laser: broad-spectrum vs. broad-spectrum with iron oxide sunscreens

Skinova Co., Ltd.0 sites30 target enrollmentStarted: April 17, 2023Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Enrolling By Invitation
Sponsor
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to N/A (No limit) (—)
Sex
All

Inclusion Criteria

  • 1. Asian with Fitzpatrick Skin type III-V
  • 2. Was diagnosed by a physician as Solar lentigines
  • 3. There are solar lentigines lesions on both sides of the face. The lesion size is greater than 6 mm.

Exclusion Criteria

  • 1. Pregnant women
  • 2. Patients with dermatitis, wounds, or skin infections on the face
  • 3. Patients with a history of allergy to anesthetics that cannot use cold air during treatment instead.
  • 4. Patients with a history of allergy to sunscreen or iron oxide allergy
  • 5. Patients with other diseases related to pigmentation abnormalities, such as melasma, hori nevus, nevus of ota, freckles, etc., in the same area as solar lentigines
  • 6. Patients with a history of herpes on the face or suffering from herpes on the face
  • 7. Patients with mental disorders whom a psychiatrist has diagnosed.
  • 8. Patients considered by the researcher to be unsafe if participating in the program
  • 9. Patients who are not allowed to take pictures for treatment evaluation

Investigators

Sponsor
Skinova Co., Ltd.

Similar Trials